GSE228430 FABP5 inhibition Huh-7 2 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE228430_FABP5 inhibition_Huh-7_2_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE228430_FABP5 inhibition_Huh-7_2_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE228430_FABP5 inhibition_Huh-7_2_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE228430_FABP5 inhibition_Huh-7_2_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

carbonic anhydrase 2

Gene

C-X-C motif chemokine ligand 8

Gene

argininosuccinate synthase 1

Gene

adhesion molecule with Ig like domain 2

Gene

aldehyde dehydrogenase 1 family member A1

Gene

interferon alpha inducible protein 6

Gene

15-hydroxyprostaglandin dehydrogenase

Gene

serine peptidase inhibitor Kazal type 1

Gene

annexin A3

Gene

lymphoid enhancer binding factor 1

  • Gene

    carbonic anhydrase 2


  • Gene

    C-X-C motif chemokine ligand 8


  • Gene

    argininosuccinate synthase 1


  • Gene

    adhesion molecule with Ig like domain 2


  • Gene

    aldehyde dehydrogenase 1 family member A1


  • Gene

    interferon alpha inducible protein 6


  • Gene

    15-hydroxyprostaglandin dehydrogenase


  • Gene

    serine peptidase inhibitor Kazal type 1



  • Gene

    lymphoid enhancer binding factor 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.